Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Molecular therapy stratification for high-risk MM: MUK Nine b OPTIMUM

Martin Kaiser • 7 Dec 2019
ASH 2019
Multiple Myeloma Bortezomib Cyclophosphamide Daratumumab Dexamethasone Lenalidomide
MUK Nine b Myeloma XI

Martin Kaiser, MD, Royal Marsden NHS Foundation Trust, London, UK, discusses the MUK Nine b: OPTIMUM Treatment Protocol (NCT03188172), a phase II trial for transplant eligible newly diagnosed multiple myeloma (NDMM) patients. This study consisted of two inter-related protocols: a molecular screening protocol and an interventional trial for high-risk NDMM identified in the molecular screening. Dr Kaiser highlights the innovative therapy used in this trial. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Martin Kaiser

3:11
Defining and identifying ultra-high-risk multiple myeloma
Martin Kaiser • 10 Dec 2023
2:26
OPTIMUM/MUKnine: the risk of early relapse in patients with ultra high-risk multiple myeloma
Martin Kaiser • 10 Dec 2023
6:34
The importance of genetic testing in high-risk multiple myeloma & targeted therapy
Martin Kaiser • 27 Aug 2022
4:08
MUK Nine b update: Dara-CVRd induction plus dara-VRd consolidation for ultra-high risk NDMM and pPCL
Martin Kaiser • 11 Dec 2021

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals